STRIVENCT07050732
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 33 words
- Primary completion pushed from Nov 2026 to Apr 2027
- Study completion pushed from Apr 2028 to Sep 2028
- Study description expanded, about 2 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 2025 to Dec 4, 2025
- Site details revised
- Minor Interventions: Arexvy (1 dose total) (Biological), Arexvy (2 doses total) (Biological), Arexvy (3 doses total) (Biological) to Arexvy (1 dose total) (Biological), Arexvy (2 doses total) (Biological), Arexvy (3 doses total) (Biological), Placebo (Other)v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Geometric Mean Titer (GMT) (ED60 RSV A and B)
Timeframe: At 30 days post 1st and 2nd dose in Arm 1 and Arm 2
Immune response elicited by adjuvanted RSVPreF3 (Arexvy) in immunocompromised adults as determined by titers of neutralizing antibody ED60 against RSV A and B
Timeframe: At 30 days post 2nd dose (Arm 2) and 30 days post 1st dose (Arm 1)
Secondary (14)
Proportion of participants reporting reactions at injection site
Proportion of participants reporting systemic events
Proportion of participants reporting adverse events
Adverse events of special interest
Serious adverse events
Show 9 moreShow less
Individual titers (ED60) for RSV-A and RSV-B #1
Individual titers (ED60) for RSV-A and RSV-B #2
Individual titers (ED60) for RSV-A and RSV-B #3
Individual titers (ED60) for RSV-A and RSV-B #4
Individual titers (ED60) for RSV-A and RSV-B #5
Individual titers (ED60) for RSV-A and RSV-B #6
Cell mediated immunity (RSV F specific CD4+ and CD8+ T cell response (T cells producing ≥ 2 cytokines, expressed as % of live CD3+)) #1
Cell mediated immunity (RSV F specific CD4+ and CD8+ T cell response (T cells producing ≥ 2 cytokines, expressed as % of live CD3+)) #2
Cell mediated immunity (RSV F specific CD4+ and CD8+ T cell response (T cells producing ≥ 2 cytokines, expressed as % of live CD3+)) #3
Arms and interventions
Arm 1: Arexvy + PlaceboExperimental
One dose of adjuvanted RSVPreF3 (Arexvy) at enrollment followed by placebo vaccine at Day 60 plus a re-vaccination Arexvy dose at 1 year (Day 365)
Arm 2: Arexvy + ArexvyExperimental
One dose of adjuvanted RSVPreF3 (Arexvy) at enrollment followed by a second dose of Arexvy at Day 60 plus a re-vaccination Arexvy dose at 1 year (Day 365)
Arm 3: Healthy ComparatorsExperimental
One dose of adjuvanted RSVPreF3 (Arexvy) at enrollment
Biologicals: Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total)
Other: Placebo
Sites
1 site in 1 country
- Johns Hopkins UniversityBaltimore, Maryland, United States